

ESPS PEER REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 14059

Title: Early kidney injury during long-term adefovir dipivoxil therapy in patients with chronic hepatitis B

Reviewer code: 00003250

Science editor: Jing Yu

Date sent for review: 2014-09-19 13:53

Date reviewed: 2014-09-29 15:17

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> Existing	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair		BPG Search:	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Existing	<input checked="" type="checkbox"/> Minor revision
		<input type="checkbox"/> No records	<input type="checkbox"/> Major revision

COMMENTS TO AUTHORS

The authors examined urine β 2-M and RBP for the detection of early renal injury during long-term ADV treatment and they showed these are sensitive biomarkers. This paper is well written and informative, but needs some modification for improvement. 1) In patients treated with LAM and ADV, ADV was added on to LAM resistance or both ADV and LAM were prescribed from the beginning? 2) Drug resistance would have been developed in some patients during a median treatment duration of 55 months, especially in patients treated with ADV monotherapy, because the frequency of ADV resistance was reported to be 29% at the 5th year (Hepatology 2007;45:1056-1075). How did the authors treat those patients with drug resistance? 3) The reference values of urine RBP and β 2-M abnormality should be shown in the text. 4) In the switching of ADV to ETV, 11 patients were switched and the other 11 were not. Were they selected at random? 5) Why there is a difference of treatment duration between 72 months in Figure 1 and 60 months in Figure 2? Minor mistakes, 1) Results of Abstract, line 7: "serum" would be serum creatinine or creatinine. 2) Page 4, line 5; "diagnosis" should be diagnose. 3) Page 6, 1st paragraph; a total of "290" CHB patients should be 330 (165+165). 4) Page 9, line 4; interleuin-18 should be interleukin-18. 5) Page 9, line 6; 19.7% should be 9.7%. 6) Page 10, line 8; "as" should be deleted. 7) In references underlines are not needed.